Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
February 06 2023 - 9:09AM
Business Wire
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced it will host a conference call and
webcast on Tuesday, February 7, 2023, at 2:00 p.m. Pacific Time
(5:00 p.m. Eastern Time) to report financial results for its fiscal
year 2023 third quarter ended December 31, 2022 and provide a
corporate update.
Event: Vistagen Fiscal Year 2023 Third Quarter Results
Conference Call Date: Tuesday, February 7, 2023 Time:
2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US Dial-in (Toll
Free): 1-877-407-9716 TOLL/International Dial-in:
1-201-493-6779 Conference ID: 13735532 Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1593644&tp_key=b10e7e1927
An audio webcast of the conference call will also be available
via the link provided above. Participants should access this
webcast site 10 minutes before the start of the call. In addition,
a telephone playback of the call will be available after
approximately 5:00 p.m. Pacific Time on Tuesday, February 7, 2023.
To listen to the replay, call toll free 1-844-512-2921 within the
United States or 1-412-317-6671 when calling internationally
(toll). Please use the replay access ID number 13735532.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. The Company is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available for
treatment of anxiety and depression. Vistagen’s product candidates
belong to a new class of drugs known as pherines, which are
designed with a novel rapid-onset mechanism of action that
activates chemosensory neurons in the nasal passages and can impact
key neural circuits without systemic uptake or direct activity on
CNS neurons in the brain. Vistagen is passionate about transforming
mental health care and redefining what is possible in the treatment
of anxiety and depression. Connect at www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230206005408/en/
Investors Mark Flather Vice President, Investor Relations
(650) 577-3617 mflather@vistagen.com
Media Nate Hitchings SKDK nhitchings@skdknick.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024